AMPHAmphastar Pharmaceuticals, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for a decline (~−9% a year). The price demands less than its three-year revenue growth of 11% a year, expectations look modest.
In its normal range: P/E 14.9 vs a 19.4 median over 33 quarters (−23% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What AMPH's price assumes
Amphastar Pharmaceuticals, Inc. trades at 14.9× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · cheaper than the typical name in its group
- Price / sales
- 1.22
Price / sales · as of 2026-Q2
- Free cash flow yield
- 14%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- −8.6%
Growth the price implies · The price pays for −8.6% free cash flow growth a year for a decade; the business has delivered +15% a year over the last three.
Details›
- Price / bookas of 2026-Q2
- 1.16
- EV / EBITas of 2026-Q2
- 10.6
- EV / salesas of 2026-Q2
- 1.66
- Healthcare median P/E503 names
- 27.9
- Drug Manufacturers - Specialty & Generic median P/E44 names
- 21.0
- Free cash flow, trailing twelve months
- $153M
- Market capitalisation42.5 million shares, counted Jul 31, 2026
- $1.07B
- 3-year revenue growth
- +11%
- 3-year free cash flow growth
- +15%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $23.89 |
| Its own P/E history, median | $32.85 |
| Its own P/E history, upper quartile | $72.86 |
| 52-week range | $16.87 – $29.40 |
| Today | $25.14 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Drug Manufacturers, Specialty & Generic
Ranks #4 of 39 by RyuScore